Affiliation:
1. Anatomy, University of Fribourg, 1700 Fribourg, Switzerland
Abstract
Clear-cell Renal-Cell Carcinoma (ccRCC) is the most common type of renal-cell carcinoma (RCC). In many cases, RCC patients manifest the first symptoms during the advanced stage of the disease. For this reason, immunotherapy appears to be one of the dominant treatments to achieve a resolution. In this review, we focus on the presentation of the main immune checkpoint proteins that act as negative regulators of immune responses, such as PD-1, CTLA-4, LAG-3, TIGIT, and TIM-3, and their respective inhibitors. Interleukin-2, another potential component of the treatment of ccRCC patients, has also been covered. The synergy between several immunotherapies is one of the main aspects that unites the conclusions of research in recent years. To date, the combination of several immunotherapies enhances the efficacy of a monotherapy, which often manifests important limitations. Immunotherapy aimed at restoring the anti-cancer immune response in ccRCC, involved in the recognition and elimination of cancer cells, may also be a valid solution for many other types of immunogenic tumors that are diagnosed in the final stages.
Reference75 articles.
1. Porth, C. (2011). Essentials of Pathophysiology: Concepts of Altered Health States, Wolters Kluwer/Lippincott Williams & Wilkins.
2. Lara, P.N., and Jonasch, E. (2012). Kidney Cancer: Principles and Practice, Springer Science & Business Media.
3. Woolf, N. (1998). Pathology: Basic and Systemic, W.B. Saunders.
4. Copstead, L.-E., and Banasik, J. (2010). Pathophysiology, Saunders Elsevier.
5. Treatment strategies for clear cell renal cell carcinoma: Past, present and future;Yang;Front. Oncol.,2023